Prevalence of vertebral fractures in patients with rheumatoid  arthritis: revisiting the role of glucocorticoids

Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : M. Ghazi & S. Kolta & K. Briot & J. Fechtenbaum & S. Paternotte & C. Roux
  • چاپ و سال / کشور: 2011

Description

Summary Vertebral fracture assessment (VFA) is a convenient tool for the diagnosis of vertebral fracture in RA. Optimal control of inflammation may be an effective means to protect against vertebral fractures. Introduction The aim of this case–control study was to assess the prevalence of vertebral fractures (VFs) in patients with RA using VFA technology. Methods Consecutive women (N=101, 56.1±14.2 years) with RA (mean disease duration, 14.9±10 years) were recruited in the study. Clinical and biological statuses and treatments including glucocorticoids were assessed. Controls (N=303), randomly selected from the general population, were individually matched to each case for age. Results The prevalences of osteoporosis were 55.4% and 10.5% in patients and controls, respectively. Among the subjects, 21.7% and 4.2% had a vertebral fracture in the RA and control groups, respectively. Compared with controls, patients with RA had an increased risk of VFs: odds ratio (OR) (CI 95%) adjusted on body mass index was 6.5 (3.1, 13.9). In a multiple logistic regression analysis, VFs were independently associated with presence of non-vertebral fractures (OR=9.2 [2.5–33.5]), presence of a fall in the previous year (OR=4.6 [1.2–18.3]), current use of diseasemodifying anti-rheumatic drugs (DMARDs) (OR=0.05 [0.004, 0.51]) and current use of steroids (OR=0.17 [0.04, 0.67]). Conclusion Rheumatoid arthritis is a risk factor of VF (OR= 6.5). VFA is a convenient tool for this diagnosis. Presence of VF is inversely related to the use of DMARD and glucocorticoids, enhancing the hypothesis that an appropriate control of the disease may be a protective factor against bone fragility.
Osteoporos Int DOI 10.1007/s00198-011-1584-3 Received: 10 November 2010 / Accepted: 11 January 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری